Sacituzumab Tirumotecan + Pembrolizumab for Cervical Cancer

This trial explores new ways to treat cervical cancer that has spread. It combines sacituzumab tirumotecan (a targeted cancer treatment) with pembrolizumab and bevacizumab to assess safety and effectiveness in extending patient survival or preventing cancer progression. Participants will join different groups to test these medicines together or against standard treatments. Individuals with recurrent or metastatic cervical cancer, who are not candidates for surgery or radiation, might be suitable for this study. As a Phase 3 trial, it represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.

The trial does not specify if you need to stop taking your current medications, but you cannot take strong inducers or inhibitors of cytochrome P450 3A4 during the treatment. It's best to discuss your current medications with the trial team.

Research has shown that sacituzumab tirumotecan (sac-TMT) is generally safe for patients with advanced cancers, though about 47.4% of patients experienced serious side effects. These side effects include low white blood cell counts (23.7%) and anemia (21.1%), which means having too few healthy red blood cells. This suggests that while the treatment is effective, it can cause significant issues for some people.

Studies indicate that pembrolizumab is mostly well-tolerated, with about 21% of patients with cervical cancer experiencing severe side effects. Pembrolizumab helps the immune system fight cancer.

Researchers are excited about Sacituzumab Tirumotecan (Sac-TMT) combined with Pembrolizumab for cervical cancer because it offers a novel approach that differs from traditional treatments like chemoradiation or cisplatin-based therapies. Sac-TMT is an antibody-drug conjugate that specifically targets cancer cells, potentially improving efficacy and reducing side effects compared to non-targeted chemotherapy. Additionally, Pembrolizumab is an immunotherapy drug that helps the immune system recognize and attack cancer cells, offering a promising alternative for patients whose cancer has not responded well to standard treatments. This combination aims to enhance the body's natural defenses while directly targeting tumors, providing a dual mechanism of action that could lead to better outcomes for patients.

Studies have shown that sacituzumab tirumotecan (sac-TMT), a treatment in this trial, helps patients with metastatic cancer live longer without disease progression. This medicine targets and attacks cancer cells directly. Pembrolizumab, another treatment option in this trial, has proven effective in extending the lives of people with metastatic cervical cancer. Specifically, research indicates that patients treated with pembrolizumab lived longer without cancer worsening compared to those who received a placebo. These medicines boost the immune system to fight cancer and directly target tumors.¹³⁶⁷⁸